Secondary cancers following allogeneic haematopoietic cell transplantation in adults

British Journal of Haematology

Volumn 154, Issue 3, 2011, Pages 301-310

  Majhail, Navneet S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

Author keywords

Allogeneic transplantation; Haematopoietic cell transplantation; Late complications; Second cancers

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GANCICLOVIR; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; EPSTEIN BARR VIRUS INFECTION; ESOPHAGUS CANCER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIP CANCER; LIVER CANCER; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; MOUTH CANCER; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SOFT TISSUE CANCER; SOLID TUMOR; T CELL DEPLETION; THYROID CANCER; TONGUE CANCER; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 79960215975     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08756.x     Document Type: Review

References (61)

1. Allan, J.M. & Travis, L.B. (2005) Mechanisms of therapy-related carcinogenesis. Nature Reviews Cancer, 5, 943-955.
2. Baker, K.S., DeFor, T.E., Burns, L.J., Ramsay, N.K., Neglia, J.P. & Robison, L.L. (2003) New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. Journal of Clinical Oncology, 21, 1352-1358.
3. Ballen, K.K., Cutler, C., Yeap, B.Y., McAfee, S.L., Dey, B.R., Attar, E.C., Chen, Y.B., Haspel, R.L., Liney, D., Koreth, J., Ho, V., Alyea, E.P., Soiffer, R.J., Spitzer, T.R. & Antin, J.H. (2010) Donor-derived second hematologic malignancies after cord blood transplantation. Biology of Blood and Marrow Transplantation, 16, 1025-1031.
4. Barker, J.N., Martin, P.L., Coad, J.E., DeFor, T., Trigg, M.E., Kurtzberg, J., Weisdorf, D.J. & Wagner, J. (2001) Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biology of Blood and Marrow Transplantation, 7, 395-399.
5. Bhatia, S., Louie, A.D., Bhatia, R., O'Donnell, M.R., Fung, H., Kashyap, A., Krishnan, A., Molina, A., Nademanee, A., Niland, J.C., Parker, P.A., Snyder, D.S., Spielberger, R., Stein, A. & Forman, S.J. (2001) Solid cancers after bone marrow transplantation. Journal of Clinical Oncology, 19, 464-471.
6. Bhatia, S., Francisco, L., Carter, A., Sun, C.L., Baker, K.S., Gurney, J.G., McGlave, P.B., Nademanee, A., O'Donnell, M., Ramsay, N.K., Robison, L.L., Snyder, D., Stein, A., Forman, S.J. & Weisdorf, D.J. (2007) Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood, 110, 3784-3792.
7. Blaes, A.H., Cao, Q., Wagner, J.E., Young, J.A., Weisdorf, D.J. & Brunstein, C.G. (2010) Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biology of Blood and Marrow Transplantation, 16, 287-291.
8. Brunstein, C.G., Weisdorf, D.J., DeFor, T., Barker, J.N., Tolar, J., van Burik, J.A. & Wagner, J.E. (2006) Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood, 108, 2874-2880.
9. Chakraborty, S., Sun, C.L., Francisco, L., Sabado, M., Li, L., Chang, K.L., Forman, S., Bhatia, S. & Bhatia, R. (2009) Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. Journal of Clinical Oncology, 27, 791-798.
10. Cohen, A., Rovelli, A., Merlo, D.F., van Lint, M.T., Lanino, E., Bresters, D., Ceppi, M., Bocchini, V., Tichelli, A. & Socie, G. (2007a) Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. Journal of Clinical Oncology, 25, 2449-2454.
11. Cohen, J.M., Cooper, N., Chakrabarti, S., Thomson, K., Samarasinghe, S., Cubitt, D., Lloyd, C., Woolfrey, A., Veys, P. & Amrolia, P.J. (2007b) EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leukaemia & Lymphoma, 48, 256-269.
12. Curtis, R.E., Rowlings, P.A., Deeg, H.J., Shriner, D.A., Socie, G., Travis, L.B., Horowitz, M.M., Witherspoon, R.P., Hoover, R.N., Sobocinski, K.A., Fraumeni, Jr, J.F. & Boice, Jr, J.D. (1997) Solid cancers after bone marrow transplantation. New England Journal of Medicine, 336, 897-904.
13. Curtis, R.E., Travis, L.B., Rowlings, P.A., Socie, G., Kingma, D.W., Banks, P.M., Jaffe, E.S., Sale, G.E., Horowitz, M.M., Witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H.J., Sullivan, K.M., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, Jr, J.F. & Deeg, H.J. (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 94, 2208-2216.
14. Curtis, R.E., Metayer, C., Rizzo, J.D., Socie, G., Sobocinski, K.A., Flowers, M.E., Travis, W.D., Travis, L.B., Horowitz, M.M. & Deeg, H.J. (2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood, 105, 3802-3811.
15. van Esser, J.W., van der Holt, B., Meijer, E., Niesters, H.G., Trenschel, R., Thijsen, S.F., van Loon, A.M., Frassoni, F., Bacigalupo, A., Schaefer, U.W., Osterhaus, A.D., Gratama, J.W., Lowenberg, B., Verdonck, L.F. & Cornelissen, J.J. (2001) Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. Blood, 98, 972-978.
16. van Esser, J.W., Niesters, H.G., van der Holt, B., Meijer, E., Osterhaus, A.D., Gratama, J.W., Verdonck, L.F., Lowenberg, B. & Cornelissen, J.J. (2002) Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood, 99, 4364-4369.
17. Faber, P., Fisch, P., Waterhouse, M., Schmitt-Graff, A., Bertz, H., Finke, J. & Spyridonidis, A. (2006) Frequent genomic alterations in epithelium measured by microsatellite instability following allogeneic hematopoietic cell transplantation in humans. Blood, 107, 3389-3396.
18. Fenske, T.S., McMahon, C., Edwin, D., Jarvis, J.C., Cheverud, J.M., Minn, M., Mathews, V., Bogue, M.A., Province, M.A., McLeod, H.L. & Graubert, T.A. (2006) Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Research, 66, 5029-5038.
19. Flynn, C.M. & Kaufman, D.S. (2007) Donor cell leukemia: insight into cancer stem cells and the stem cell niche. Blood, 109, 2688-2692.
20. Friedman, D.L., Rovo, A., Leisenring, W., Locasciulli, A., Flowers, M.E., Tichelli, A., Sanders, J.E., Deeg, H.J. & Socie, G. (2008) Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood, 111, 939-944.
21. Gallagher, G. & Forrest, D.L. (2007) Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer, 109, 84-92.
22. Gulley, M.L. & Tang, W. (2010) Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clinical Microbiology Reviews, 23, 350-366.
23. Gustafsson, A., Levitsky, V., Zou, J.Z., Frisan, T., Dalianis, T., Ljungman, P., Ringden, O., Winiarski, J., Ernberg, I. & Masucci, M.G. (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood, 95, 807-814.
24. Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P.L., Kelly, D., MacGilchrist, A., Gandhi, M.K., Swerdlow, A.J. & Crawford, D.H. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 1123-1131.
25. Hertenstein, B., Hambach, L., Bacigalupo, A., Schmitz, N., McCann, S., Slavin, S., Gratwohl, A., Ferrant, A., Elmaagacli, A., Schwertfeger, R., Locasciulli, A., Zander, A., Bornhauser, M., Niederwieser, D. & Ruutu, T. (2005) Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 90, 969-975.
26. Heslop, H.E. (2009) How I treat EBV lymphoproliferation. Blood, 114, 4002-4008.
27. Khan, F.M., Sy, S., Louie, P., Ugarte-Torres, A., Berka, N., Sinclair, G.D., Stewart, D.A., Russell, J.A. & Storek, J. (2010) Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa. Blood, 116, 1803-1806.
28. Kolb, H.J., Socie, G., Duell, T., Van Lint, M.T., Tichelli, A., Apperley, J.F., Nekolla, E., Ljungman, P., Jacobsen, N., van Weel, M., Wick, R., Weiss, M. & Prentice, H.G. (1999) Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Annals of Internal Medicine, 131, 738-744.
29. Krams, S.M. & Martinez, O.M. (2008) Epstein-Barr virus, rapamycin, and host immune responses. Current Opinion in Organ Transplantation, 13, 563-568.
30. Landgren, O., Gilbert, E.S., Rizzo, J.D., Socie, G., Banks, P.M., Sobocinski, K.A., Horowitz, M.M., Jaffe, E.S., Kingma, D.W., Travis, L.B., Flowers, M.E., Martin, P.J., Deeg, H.J. & Curtis, R.E. (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood, 113, 4992-5001.
31. Leisenring, W., Friedman, D.L., Flowers, M.E., Schwartz, J.L. & Deeg, H.J. (2006) Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. Journal of Clinical Oncology, 24, 1119-1126.
32. Loren, A.W. & Tsai, D.E. (2005) Post-transplant lymphoproliferative disorder. Clinics in Chest Medicine, 26, 631-645. vii.
33. Lowe, T., Bhatia, S. & Somlo, G. (2007) Second malignancies after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 13, 1121-1134.
34. Lucas, K.G., Burton, R.L., Zimmerman, S.E., Wang, J., Cornetta, K.G., Robertson, K.A., Lee, C.H. & Emanuel, D.J. (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood, 91, 3654-3661.
35. Majhail, N.S. (2008) Old and new cancers after hematopoietic-cell transplantation. Hematology/The Education Program of the American Society of Hematology, 142-149.
36. Majhail, N.S., Brazauskas, R., Rizzo, J.D., Sobecks, R.M., Wang, Z., Horowitz, M.M., Bolwell, B., Wingard, J.R. & Socie, G. (2011) Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood, 117, 316-322.
37. Martin, P.J., Counts, Jr, G.W., Appelbaum, F.R., Lee, S.J., Sanders, J.E., Deeg, H.J., Flowers, M.E., Syrjala, K.L., Hansen, J.A., Storb, R.F. & Storer, B.E. (2010) Life expectancy in patients surviving more than 5years after hematopoietic cell transplantation. Journal of Clinical Oncology, 28, 1011-1016.
38. Omar, H., Hagglund, H., Gustafsson-Jernberg, A., LeBlanc, K., Mattsson, J., Remberger, M., Ringden, O., Sparrelid, E., Sundin, M., Winiarski, J., Yun, Z. & Ljungman, P. (2009) Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transplant Infectious Disease, 11, 393-399.
39. O'Reilly, R.J., Doubrovina, E., Trivedi, D., Hasan, A., Kollen, W. & Koehne, G. (2007) Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunologic Research, 38, 237-250.
40. Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Small, T.N., Young, J.W., Kernan, N.A. & O'Reilly, R.J. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New England Journal of Medicine, 330, 1185-1191.
41. Parker, A., Bowles, K., Bradley, J.A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A. & Newstead, C. (2010a) Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. British Journal of Haematology, 149, 675-692.
42. Parker, A., Bowles, K., Bradley, J.A., Emery, V., Featherstone, C., Gupte, G., Marcus, R., Parameshwar, J., Ramsay, A. & Newstead, C. (2010b) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. British Journal of Haematology, 149, 693-705.
43. Pulsipher, M.A., Chitphakdithai, P., Miller, J.P., Logan, B.R., King, R.J., Rizzo, J.D., Leitman, S.F., Anderlini, P., Haagenson, M.D., Kurian, S., Klein, J.P., Horowitz, M.M. & Confer, D.L. (2009) Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood, 113, 3604-3611.
44. Reddy, N., Rezvani, K., Barrett, A.J. & Savani, B.N. (2011) Strategies to prevent EBV reactivation and post- transplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biology of Blood and Marrow Transplantation, 17, 591-597.
45. Rizzo, J.D., Wingard, J.R., Tichelli, A., Lee, S.J., Van Lint, M.T., Burns, L.J., Davies, S.M., Ferrara, J.L. & Socie, G. (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 12, 138-151.
46. Rizzo, J.D., Curtis, R.E., Socie, G., Sobocinski, K.A., Gilbert, E., Landgren, O., Travis, L.B., Travis, W.D., Flowers, M.E., Friedman, D.L., Horowitz, M.M., Wingard, J.R. & Deeg, H.J. (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood, 113, 1175-1183.
47. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., Srivastava, D.K., Bowman, L.C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-1555.
48. Savani, B.N., Stratton, P., Shenoy, A., Kozanas, E., Goodman, S. & Barrett, A.J. (2008) Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination. Biology of Blood and Marrow Transplantation, 14, 1072-1075.
49. Savani, B.N., Goodman, S. & Barrett, A.J. (2009) Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clinical Cancer Research, 15, 2219-2221.
50. Schwartz, J.L., Kopecky, K.J., Mathes, R.W., Leisenring, W.M., Friedman, D.L. & Deeg, H.J. (2009) Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiation Research, 171, 155-163.
51. Smith, R.A., Cokkinides, V., Brooks, D., Saslow, D. & Brawley, O.W. (2010) Cancer Screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA: A Cancer Journal for Clinicians, 60, 99-119.
52. Socie, G., Stone, J.V., Wingard, J.R., Weisdorf, D., Henslee-Downey, P.J., Bredeson, C., Cahn, J.Y., Passweg, J.R., Rowlings, P.A., Schouten, H.C., Kolb, H.J. & Klein, J.P. (1999) Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. New England Journal of Medicine, 341, 14-21.
53. Socie, G., Curtis, R.E., Deeg, H.J., Sobocinski, K.A., Filipovich, A.H., Travis, L.B., Sullivan, K.M., Rowlings, P.A., Kingma, D.W., Banks, P.M., Travis, W.D., Witherspoon, R.P., Sanders, J., Jaffe, E.S. & Horowitz, M.M. (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. Journal of Clinical Oncology, 18, 348-357.
54. Styczynski, J., Reusser, P., Einsele, H., de la Camara, R., Cordonnier, C., Ward, K.N., Ljungman, P. & Engelhard, D. (2009) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplantation, 43, 757-770.
55. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon.
56. Themeli, M., Petrikkos, L., Waterhouse, M., Bertz, H., Lagadinou, E., Zoumbos, N., Finke, J. & Spyridonidis, A. (2010) Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia. Leukemia, 24, 536-543.
57. Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J.R., Young, J.A. & Boeckh, M.J. (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biology of Blood and Marrow Transplantation, 15, 1143-1238.
58. Wagner, H.J., Cheng, Y.C., Huls, M.H., Gee, A.P., Kuehnle, I., Krance, R.A., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2004) Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood, 103, 3979-3981.
59. Weinstock, D.M., Ambrossi, G.G., Brennan, C., Kiehn, T.E. & Jakubowski, A. (2006) Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplantation, 37, 539-546.
60. Witherspoon, R.P., Deeg, H.J. & Storb, R. (1994) Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation, 57, 1413-1418.
61. Wynn, R.F., Cross, M.A., Hatton, C., Will, A.M., Lashford, L.S., Dexter, T.M. & Testa, N.G. (1998) Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet, 351, 178-181.